CION Ameerpet
Primary central nervous system lymphoma (CNS lymphoma) is a rare, aggressive non-Hodgkin lymphoma that starts inside the brain, spinal cord or eyes. Because it sits behind the blood-brain barrier, it is treated very differently from other brain tumours — this guide explains how, and how CION's combined haemato-oncology and neuro-oncology team plans care.
Primary central nervous system lymphoma (PCNSL) — commonly shortened to CNS lymphoma or brain lymphoma — is a rare, aggressive form of non-Hodgkin lymphoma that begins inside, and stays confined to, the central nervous system: the brain, the spinal cord, the eyes, and the coverings of the brain (the meninges). It is called primary because it starts in these tissues, rather than spreading there from lymphoma elsewhere in the body.
Although it grows in the brain, PCNSL is a cancer of immune (lymphoid) cells, not of brain cells. The overwhelming majority are diffuse large B-cell lymphomas — the same cell type as DLBCL elsewhere in the body — and are typically CD20-positive. What makes CNS lymphoma distinct is its location behind the blood-brain barrier, a protective filter that keeps many drugs out of the brain. This single fact reshapes the entire treatment approach.
This guide explains the symptoms of CNS lymphoma, how it is diagnosed, how it is treated, and what the outlook looks like. For the wider picture of lymphoma care, see our Lymphoma hub and our Lymphoma Treatment in Hyderabad page. If your research is about brain tumours in general, our Brain Cancer & Tumour hub covers those separately.
Primary CNS lymphoma is one of the few brain tumours that is not treated by surgical removal. Because it is exquisitely sensitive to chemotherapy and is often deep or multifocal, surgery is generally used only to take a biopsy — the treatment itself is high-dose chemotherapy able to cross the blood-brain barrier. Attempting to remove it surgically does not improve outcomes and risks neurological harm. (Source: NCCN and ESMO guidelines for primary CNS lymphoma.)
On a scan, brain lymphoma can look like a glioma or a brain metastasis — but it is a lymphoma, and that changes everything about how it is treated.
PCNSL arises from immune cells, so — unlike the brain tumours covered on our Brain Cancer hub — it responds dramatically to chemotherapy and antibody therapy. This is why a tissue diagnosis before treatment is essential.
The barrier that protects the brain also blocks many cancer drugs. Effective treatment relies on specific high-dose chemotherapy chosen precisely because it can penetrate the central nervous system.
Because the tumour is often deep or in several places and melts away with chemotherapy, surgery is generally limited to a stereotactic biopsy. Removing it surgically does not improve survival.
A weakened immune system is the main risk factor, and lymphoma of the nervous system can also arise as post-transplant lymphoproliferative disorder. HIV testing and a medication review are part of every work-up.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just received a CNS lymphoma diagnosis, waiting on a biopsy result, or want a second opinion before treatment begins? CION's combined haemato-oncology and neuro-oncology team is here to help.
Symptoms of primary central nervous system lymphoma usually build over a few weeks and depend on where in the brain the tumour lies. Because PCNSL often affects the deep and frontal parts of the brain, changes in thinking and behaviour are common early signs. Warning signs include:
These symptoms overlap with many ordinary and non-cancerous conditions. But any symptom that is new, persistent and steadily progressive should be checked with a brain MRI and specialist review. Speak to a CION specialist if you have these signs or a confirmed CNS lymphoma.
Confirming CNS lymphoma — and proving it is confined to the nervous system — follows a careful, step-by-step pathway. CION delivers the imaging coordination, molecular testing, staging and review directly.
A contrast MRI is the first and most important scan. CNS lymphoma typically appears as one or more strongly enhancing lesions, often near the deep midline structures. The pattern can suggest lymphoma, but imaging alone cannot confirm it.
A definitive diagnosis needs tissue. This is usually obtained by a minimally invasive stereotactic needle biopsy, coordinated with accredited neurosurgical partners — not by removing the tumour, because PCNSL is treated with drug therapy. The pathologist confirms the lymphoma and its cell-of-origin markers; most are CD20-positive B-cell tumours, which guides antibody therapy. Where possible, steroids are held before biopsy, since they can temporarily shrink the tumour and obscure the diagnosis.
Because the diagnosis of primary CNS lymphoma requires that no lymphoma exists elsewhere, the work-up includes a slit-lamp eye examination, a lumbar puncture to sample the spinal fluid where it is safe, body imaging, and a bone-marrow assessment. HIV testing is standard because immunosuppression is a major risk factor. If lymphoma is found outside the nervous system, the diagnosis and treatment change — a distinction covered on our extranodal lymphoma page.
Steroids can make primary CNS lymphoma temporarily "melt away" on a scan — which is why they are called a ghost tumour. Because steroids can shrink the lymphoma and make a biopsy non-diagnostic, guidelines advise avoiding them before the biopsy whenever it is medically safe to do so, so the tissue diagnosis is not lost. (Source: ESMO and NCCN primary CNS lymphoma guidelines.)
Every case is planned by CION's combined haemato-oncology and neuro-oncology tumour board, and tailored to your age, fitness and how the disease responds. The building blocks are described here by their mechanism; specific drug regimens are individualised and discussed on the Lymphoma Treatment in Hyderabad page.
The backbone of treatment is high-dose chemotherapy chosen because it can cross the blood-brain barrier and reach the tumour. This induction phase aims to clear the lymphoma from the brain. It is delivered directly by CION's medical oncology team, with careful monitoring of kidney function and blood counts throughout.
Because most CNS lymphomas are CD20-positive B-cell tumours, an anti-CD20 monoclonal antibody is frequently added to chemotherapy to target the lymphoma cells directly. CION delivers antibody-based (immunotherapy) treatment in-house.
After a good response, treatment is often consolidated to reduce the chance of relapse. Depending on age and fitness, this may be further systemic therapy, whole-brain radiation therapy (IMRT) delivered directly by CION, or a referral for high-dose therapy with autologous stem-cell support — the transplant step coordinated through an accredited partner facility, never performed in-house. Radiation is used thoughtfully, especially in older patients, to balance disease control against long-term effects on memory and thinking.
Alongside cancer treatment, CION manages steroids, seizure control, rehabilitation and the cognitive support many patients need. Long-term follow-up watches for relapse and for late effects of treatment — part of our survivorship care.
Primary CNS lymphoma is aggressive, but it is treatable, and outcomes have improved considerably over the last two decades with modern brain-penetrating regimens. A meaningful proportion of patients — especially those who are younger and fit enough for intensive high-dose therapy and consolidation — achieve durable, long-lasting remission.
Published series referenced by NCCN and ESMO report long-term survival ranging from a substantial minority to around half of carefully selected patients, but these numbers vary widely. For context, more common lymphomas carry different published survival ranges — Hodgkin lymphoma is often quoted at roughly 80–90% and systemic DLBCL at around 60–70% in published series — but PCNSL behaves differently because of its location in the brain. Outlook here depends heavily on age, general health, how completely the lymphoma responds to treatment, and whether the deep brain structures are involved.
Figures vary by individual and are drawn from published series, not CION-specific data. A personalised estimate from your treating team — based on your scans, biopsy and response — is far more meaningful than any single headline number.
CNS lymphoma is part of the wider family of aggressive B-cell non-Hodgkin lymphomas. If you are researching your subtype, these related pages may help:
To speak to CION's lymphoma team, see our Best Lymphoma Doctors in Hyderabad and Best Lymphoma Hospital in Hyderabad pages.
A CNS lymphoma diagnosis moves quickly and carries real nuance, so a second opinion is especially valuable in these situations:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around healing, not billing — with transparent costs explained up front. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's combined haemato-oncology and neuro-oncology team — especially valuable if the diagnosis or staging is not yet complete.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Primary central nervous system lymphoma (PCNSL), often called CNS lymphoma or brain lymphoma, is a rare, aggressive non-Hodgkin lymphoma that begins inside the brain, spinal cord, the eyes or the coverings of the brain (the meninges) — and, crucially, is confined to these areas without lymph-node disease elsewhere. The great majority are diffuse large B-cell lymphomas, so PCNSL shares its cell type with DLBCL but behaves and is treated very differently because the tumour sits behind the blood-brain barrier. Because it is uncommon and confined to the nervous system, it needs a coordinated haemato-oncology and neuro-oncology team from the outset.
Symptoms usually develop over a few weeks and reflect where the tumour sits in the brain. The commonest are changes in thinking, memory, behaviour or personality — often noticed by family first. Other signs include weakness or numbness on one side of the body, unsteadiness, speech difficulty, headaches, nausea, seizures, and — when the eyes are involved — blurred or floating vision. Because PCNSL can affect the eyes, an eye examination is part of the work-up. These symptoms overlap with many other brain conditions, so imaging and a tissue diagnosis are needed to confirm the cause. Any new, persistent and progressive neurological symptom should prompt an MRI and specialist review rather than waiting.
Diagnosis starts with a contrast MRI of the brain, which typically shows one or more contrast-enhancing lesions, often near the deep midline structures. A definitive diagnosis, however, needs tissue — usually a stereotactic needle biopsy, coordinated with accredited neurosurgical partners, since PCNSL is treated with drug therapy rather than surgical removal. The pathologist confirms the lymphoma and its cell-of-origin markers (most are CD20-positive B-cell tumours). The work-up also includes an eye (slit-lamp) examination, a lumbar puncture to check the spinal fluid where safe, and body imaging plus a bone-marrow assessment to prove the disease is confined to the nervous system. HIV testing is done because immunosuppression is a known risk factor.
Unlike most brain tumours, primary CNS lymphoma is not treated by removing it surgically — surgery is generally only for the biopsy. The backbone of treatment is high-dose chemotherapy able to cross the blood-brain barrier, often combined with an anti-CD20 monoclonal antibody, delivered directly by CION's medical oncology team. Depending on response, age and fitness, this may be consolidated with further systemic therapy, or radiation to the brain (which CION delivers as IMRT), or a referral for high-dose therapy with autologous stem-cell support — the transplant step coordinated through an accredited partner facility. Every case is planned by a combined haemato-oncology and neuro-oncology tumour board. Specific drug regimens are individualised and discussed on the Treatment page.
Primary CNS lymphoma is aggressive, but it is treatable and a meaningful proportion of patients achieve long-lasting remission — particularly younger, fitter people who can receive intensive high-dose chemotherapy and consolidation. Outcomes have improved substantially over the last two decades with modern blood-brain-barrier-penetrating regimens. Published series (referenced by NCCN and ESMO) report long-term survival in a substantial minority to around half of selected patients, but figures vary widely by age, general health, how completely the lymphoma responds, and whether the deep brain structures are involved. Because the ranges are wide and depend heavily on individual factors, an honest, personalised estimate from your treating team is far more useful than a single headline number.
PCNSL grows in the brain, so on a scan it can look like a primary brain tumour or a secondary (metastatic) deposit — but it is a lymphoma, a cancer of immune cells, not of brain or glial cells. That distinction changes everything: gliomas are usually treated with maximal safe surgery, whereas CNS lymphoma responds dramatically to chemotherapy and is rarely removed surgically. This is exactly why a tissue biopsy is essential before treatment. If you are researching brain tumours more broadly, see our Brain Cancer & Tumour hub; if the concern is lymphoma, our Lymphoma hub and Lymphoma Treatment in Hyderabad page cover diagnosis and care.
The single most important risk factor is a weakened immune system. This includes people with HIV, those on long-term immunosuppressive medication, and organ- or stem-cell transplant recipients — in whom lymphoma of the nervous system can arise as part of post-transplant lymphoproliferative disorder (PTLD). Increasing age is also a factor, with most cases occurring after 60. In immunocompromised patients the Epstein-Barr virus is frequently involved. That said, PCNSL can occur in people with no risk factors at all. Because immune status changes both the diagnosis and the treatment plan, HIV testing and a careful review of immunosuppressive medicines are a routine part of the work-up.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.